

Timothy Beukelman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2137795/timothy-beukelman-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

6,005
citations

39
h-index

76
g-index

134
ext. papers

7,080
ext. citations

5.1
avg, IF

5.39
L-index

#	Paper	IF	Citations
110	Biologic Switching Among Nonsystemic Juvenile Idiopathic Arthritis Patients: A Cohort Study in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2021 , 48, 1322-1329	4.1	3
109	Juvenile Spondyloarthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: High Biologic Use, Low Prevalence of HLA-B27, and Equal Sex Representation in Sacroiliitis. <i>Arthritis Care and Research</i> , 2021 , 73, 940-946	4.7	3
108	Oral Glucocorticoids and Incident Treatment of Diabetes Mellitus, Hypertension, and Venous Thromboembolism in Children. <i>American Journal of Epidemiology</i> , 2021 , 190, 403-412	3.8	2
107	Making Decisions About Stopping Medicines for Well-Controlled Juvenile Idiopathic Arthritis: A Mixed-Methods Study of Patients and Caregivers. <i>Arthritis Care and Research</i> , 2021 , 73, 374-385	4.7	5
106	Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Pediatric Rheumatology</i> , 2021 , 19, 131	3.5	1
105	Optimizing the Start Time of Biologics in Polyarticular Juvenile Idiopathic Arthritis: A Comparative Effectiveness Study of Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans. <i>Arthritis and Rheumatology</i> , 2021 , 73, 1898-1909	9.5	7
104	Pharmacosurveillance in Juvenile Idiopathic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2021 , 47, 643-653	2.4	1
103	New Medications Are Needed for Children With Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1945-1951	9.5	15
102	Reply. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1040-1041	9.5	
101	Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis. <i>Arthritis and Rheumatology</i> , 2020 , 72, 326-334	9.5	114
100	The prevalence of localised scleroderma in childhood assessed in the administrative claims data from the United States.. <i>Journal of Scleroderma and Related Disorders</i> , 2019 , 4, 77-78	2.3	3
99	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Arthritis Care and Research</i> , 2019 , 71, 703-716	4.7	85
98	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. <i>Arthritis Care and Research</i> , 2019 , 71, 717-734	4.7	76
97	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Treatment of Juvenile Idiopathic Arthritis: Therapeutic Approaches for Non-Systemic Polyarthritis, Sacroiliitis, and Enthesitis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 846-863	9.5	54
96	2019 American College of Rheumatology/Arthritis Foundation Guideline for the Screening, Monitoring, and Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 864-877	9.5	33
95	Childhood Arthritis and Rheumatology Research Alliance Consensus Treatment Plans for Juvenile Idiopathic Arthritis-Associated and Idiopathic Chronic Anterior Uveitis. <i>Arthritis Care and Research</i> , 2019 , 71, 482-491	4.7	37
94	Juvenile Idiopathic Arthritis 2019 , 723-733.e1		

93	Toward Accelerated Authorization and Access to New Medicines for Juvenile Idiopathic Arthritis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1976-1984	9.5	5
92	Primary Oral Presentation of Sarcoidosis in a Pediatric Patient. <i>Journal of Oral and Maxillofacial Surgery</i> , 2019 , 77, 1180-1186	1.8	1
91	Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review. <i>Pediatric Rheumatology</i> , 2019 , 17, 77	3.5	9
90	Serum S100A8/A9 and S100A12 Levels in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis: Relationship to Maintenance of Clinically Inactive Disease During Anti-Tumor Necrosis Factor Therapy and Occurrence of Disease Flare After Discontinuation of Therapy. <i>Arthritis and Rheumatology</i> , 2018 , 60, 1508-1518	9.5	23
89	Risk, Timing, and Predictors of Disease Flare After Discontinuation of Anti-Tumor Necrosis Factor Therapy in Children With Polyarticular Forms of Juvenile Idiopathic Arthritis With Clinically Inactive Disease. <i>Arthritis and Rheumatology</i> , 2018 , 70, 1508-1518	9.5	17
88	Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors. <i>Annals of the Rheumatic Diseases</i> , 2018 , 77, 1012-1016	2.4	33
87	High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy. <i>Arthritis and Rheumatology</i> , 2018 , 70, 594-605	9.5	8
86	Bayesian comparative effectiveness study of four consensus treatment plans for initial management of systemic juvenile idiopathic arthritis: FiRst-Line Options for Systemic juvenile idiopathic arthritis Treatment (FROST). <i>Clinical Trials</i> , 2018 , 15, 268-277	2.2	13
85	Comparative Effectiveness of Tumor Necrosis Factor Agents and Disease-modifying Antirheumatic Therapy in Children with Enthesitis-related Arthritis: The First Year after Diagnosis. <i>Journal of Rheumatology</i> , 2018 , 45, 107-114	4.1	9
84	Association of Statin Exposure With Histologically Confirmed Idiopathic Inflammatory Myositis in an Australian Population. <i>JAMA Internal Medicine</i> , 2018 , 178, 1224-1229	11.5	8
83	Juvenile Idiopathic Arthritis: Oligoarthritis and Polyarthritis. <i>Pediatric Clinics of North America</i> , 2018 , 65, 657-674	3.6	20
82	Assessing the prevalence of juvenile systemic sclerosis in childhood using administrative claims data from the United States.. <i>Journal of Scleroderma and Related Disorders</i> , 2018 , 3, 189-190	2.3	12
81	Rituximab treatment for chronic steroid-dependent Henoch-Schonlein purpura: 8 cases and a review of the literature. <i>Pediatric Rheumatology</i> , 2018 , 16, 71	3.5	24
80	Risk Factors for Intraarticular Heterotopic Bone Formation in the Temporomandibular Joint in Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2018 , 45, 1301-1307	4.1	14
79	Attitudes and Approaches for Withdrawing Drugs for Children with Clinically Inactive Nonsystemic JIA: A Survey of the Childhood Arthritis and Rheumatology Research Alliance. <i>Journal of Rheumatology</i> , 2017 , 44, 352-360	4.1	16
78	Changing Trends in Opioid Use Among Patients With Rheumatoid Arthritis in the United States. <i>Arthritis and Rheumatology</i> , 2017 , 69, 1733-1740	9.5	40
77	Race, Income, and Disease Outcomes in Juvenile Dermatomyositis. <i>Journal of Pediatrics</i> , 2017 , 184, 38-44	4.61	26
76	Risk of tuberculosis among Alabama children and adolescents treated with tumor necrosis factor inhibitors: a retrospective study. <i>Pediatric Rheumatology</i> , 2017 , 15, 79	3.5	6

75	Biologic Agents in the Treatment of Childhood-Onset Rheumatic Disease. <i>Journal of Pediatrics</i> , 2017 , 189, 31-39	3.6	1
74	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017 , 44, 1884-1888	4.1	8
73	Pilot study comparing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) systemic Juvenile Idiopathic Arthritis Consensus Treatment Plans. <i>Pediatric Rheumatology</i> , 2017 , 15, 23	3.5	28
72	The new Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry: design, rationale, and characteristics of patients enrolled in the first 12 months. <i>Pediatric Rheumatology</i> , 2017 , 15, 30	3.5	43
71	A survey of national and multi-national registries and cohort studies in juvenile idiopathic arthritis: challenges and opportunities. <i>Pediatric Rheumatology</i> , 2017 , 15, 31	3.5	17
70	Methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis. <i>Pediatric Rheumatology</i> , 2017 , 15, 52	3.5	14
69	Multicenter inception cohort of enthesitis-related arthritis: variation in disease characteristics and treatment approaches. <i>Arthritis Research and Therapy</i> , 2017 , 19, 84	5.7	27
68	Trial Design, Measurement, and Analysis of Clinical Investigations 2016 , 54-77.e2		1
67	Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare. <i>Arthritis and Rheumatology</i> , 2016 , 68, 56-66	9.5	101
66	Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. <i>JAMA Dermatology</i> , 2016 , 152, 164-72	5.1	88
65	The risk of hospitalized infection following initiation of biologic agents versus methotrexate in the treatment of juvenile idiopathic arthritis. <i>Arthritis Research and Therapy</i> , 2016 , 18, 210	5.7	30
64	Cost-Effectiveness Analysis of First-Line Treatment With Biologic Agents in Polyarticular Juvenile Idiopathic Arthritis. <i>Arthritis Care and Research</i> , 2016 , 68, 1803-1811	4.7	9
63	Analysis of health care claims during the peri-transfer stage of transition from pediatric to adult care among juvenile idiopathic arthritis patients. <i>Pediatric Rheumatology</i> , 2016 , 14, 49	3.5	9
62	A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis. <i>Journal of Immunology</i> , 2016 , 196, 2492-503	5.3	58
61	Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. <i>Journal of Rheumatology</i> , 2015 , 42, 541-6	4.1	33
60	Risks of herpes zoster in patients with rheumatoid arthritis according to biologic disease-modifying therapy. <i>Arthritis Care and Research</i> , 2015 , 67, 731-6	4.7	82
59	Magnetic Resonance Imaging Findings following Intraarticular Infliximab Therapy for Refractory Temporomandibular Joint Arthritis among Children with Juvenile Idiopathic Arthritis. <i>Journal of Rheumatology</i> , 2015 , 42, 2155-9	4.1	12
58	Impact of biologic agents with and without concomitant methotrexate and at reduced doses in older rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2015 , 67, 624-32	4.7	25

57	Risk of hospitalised infection in rheumatoid arthritis patients receiving biologics following a previous infection while on treatment with anti-TNF therapy. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1065-71	2.4	64
56	Novel method to collect medication adverse events in juvenile arthritis: results from the childhood arthritis and rheumatology research alliance enhanced drug safety surveillance project. <i>Arthritis Care and Research</i> , 2015 , 67, 529-37	4.7	7
55	Imaging of the temporomandibular joint in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2014 , 66, 47-54	4.7	41
54	Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAFETY Assessment of Biologic ThERapy (SABER) study. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1942-8	2.4	77
53	Changes in body mass index in children with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors. <i>Journal of Rheumatology</i> , 2014 , 41, 113-8	4.1	5
52	Adding canakinumab to the Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for systemic juvenile idiopathic arthritis: Comment on the article by DeWitt et al. <i>Arthritis Care and Research</i> , 2014 , 66, 1430-1	4.7	23
51	A20: Understanding the Use and Biology of TNF Therapy in JIA Clinical Outcomes. <i>Arthritis and Rheumatology</i> , 2014 , 66, S31-S32	9.5	1
50	Development and retrospective validation of the juvenile spondyloarthritis disease activity index. <i>Arthritis Care and Research</i> , 2014 , 66, 1775-82	4.7	49
49	Recent trends in medication usage for the treatment of juvenile idiopathic arthritis and the influence of tumor necrosis factor inhibitors. <i>Journal of Rheumatology</i> , 2014 , 41, 2078-84	4.1	11
48	Risk of malignancy associated with biologic agents in pediatric rheumatic disease. <i>Current Opinion in Rheumatology</i> , 2014 , 26, 538-42	5.3	12
47	Treatment advances in systemic juvenile idiopathic arthritis. <i>F1000prime Reports</i> , 2014 , 6, 21		26
46	Retinal vasculitis in two pediatric patients with systemic lupus erythematosus: a case report. <i>Pediatric Rheumatology</i> , 2013 , 11, 25	3.5	20
45	Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. <i>JAMA - Journal of the American Medical Association</i> , 2013 , 309, 887-95	27.4	162
44	What is the background incidence of malignancy in children with rheumatic disease?. <i>Current Rheumatology Reports</i> , 2013 , 15, 310	4.9	21
43	2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis and Rheumatism</i> , 2013 , 65, 2499-512		177
42	2013 update of the 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: recommendations for the medical therapy of children with systemic juvenile idiopathic arthritis and tuberculosis screening among children receiving biologic medications. <i>Arthritis Care and Research</i> , 2013 , 65, 1551-63	4.7	70
41	Tumor necrosis factor inhibitor therapy and cancer risk in chronic immune-mediated diseases. <i>Arthritis and Rheumatism</i> , 2013 , 65, 48-58		87
40	Infectious complications in juvenile idiopathic arthritis. <i>Current Rheumatology Reports</i> , 2013 , 15, 327	4.9	18

39	Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biologic ThERapy (SABER) Study. <i>American Journal of Ophthalmology</i> , 2013 , 155, 183-189.e1	4.9	46
38	Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis. <i>Arthritis and Rheumatism</i> , 2013 , 65, 1384-9		43
37	Race, ethnicity, and disease outcomes in juvenile idiopathic arthritis: a cross-sectional analysis of the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. <i>Journal of Rheumatology</i> , 2013 , 40, 936-42	4.1	30
36	High doses of infliximab in the management of juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2013 , 40, 1749-55	4.1	46
35	Using registries to identify adverse events in rheumatic diseases. <i>Pediatrics</i> , 2013 , 132, e1384-94	7.4	21
34	Juvenile idiopathic arthritis 2013 , 637-647		1
33	Improving the efficiency and effectiveness of pragmatic clinical trials in older adults in the United States. <i>Contemporary Clinical Trials</i> , 2012 , 33, 1211-6	2.3	21
32	Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. <i>Journal of Rheumatology</i> , 2012 , 39, 1867-74	4.1	63
31	Intra-articular corticosteroid injections to the temporomandibular joints are safe and appear to be effective therapy in children with juvenile idiopathic arthritis. <i>Journal of Oral and Maxillofacial Surgery</i> , 2012 , 70, 1802-7	1.8	63
30	Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients. <i>Arthritis Care and Research</i> , 2012 , 64, 1480-9	4.7	39
29	Back mobility and interincisor distance ranges in racially diverse North American healthy children and relationship to generalized hypermobility. <i>Pediatric Rheumatology</i> , 2012 , 10, 17	3.5	7
28	Consensus treatment plans for new-onset systemic juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 1001-10	4.7	114
27	Rates of malignancy associated with juvenile idiopathic arthritis and its treatment. <i>Arthritis and Rheumatism</i> , 2012 , 64, 1263-71		129
26	Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment. <i>Arthritis and Rheumatism</i> , 2012 , 64, 2773-80		113
25	2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. <i>Arthritis Care and Research</i> , 2012 , 64, 625-39	4.7	1199
24	Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. <i>Journal of Rheumatology</i> , 2012 , 39, 2341-51	4.1	59
23	Risk factors for temporomandibular joint arthritis in children with juvenile idiopathic arthritis. <i>Journal of Rheumatology</i> , 2012 , 39, 1880-7	4.1	80
22	Geographic distribution of endemic fungal infections among older persons, United States. <i>Emerging Infectious Diseases</i> , 2011 , 17, 1664-9	10.2	134

21	High prevalence of myositis in a southeastern United States pediatric systemic lupus erythematosus cohort. <i>Pediatric Rheumatology</i> , 2011 , 9, 20	3.5	12
20	Study design for a comprehensive assessment of biologic safety using multiple healthcare data systems. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 1199-209	2.6	28
19	Measuring process of arthritis care: a proposed set of quality measures for the process of care in juvenile idiopathic arthritis. <i>Arthritis Care and Research</i> , 2011 , 63, 10-6	4.7	42
18	2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. <i>Arthritis Care and Research</i> , 2011 , 63, 465-82	4.7	53 ¹
17	Combination therapy of abatacept and anakinra in children with refractory systemic juvenile idiopathic arthritis: a retrospective case series. <i>Journal of Rheumatology</i> , 2011 , 38, 180-1	4.1	58
16	Initiation of tumor necrosis factor- α antagonists and the risk of hospitalization for infection in patients with autoimmune diseases. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2331-9	27.4	25 ⁶
15	The comparative risk of serious infections among rheumatoid arthritis patients starting or switching biological agents. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 1401-6	2.4	77
14	Temporomandibular joint arthritis in pediatric sjogren disease and sarcoidosis. <i>Journal of Rheumatology</i> , 2011 , 38, 2272-3	4.1	7
13	Attainment of inactive disease status following initiation of TNF- α inhibitor therapy for juvenile idiopathic arthritis: enthesitis-related arthritis predicts persistent active disease. <i>Journal of Rheumatology</i> , 2011 , 38, 2675-81	4.1	43
12	Type 1 hyperlipoproteinemia and recurrent acute pancreatitis due to lipoprotein lipase antibody in a young girl with Sjogren's syndrome. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011 , 96, 3302-7	5.6	22
11	Cost-effectiveness of multifaceted evidence implementation programs for the prevention of glucocorticoid-induced osteoporosis. <i>Osteoporosis International</i> , 2010 , 21, 1573-84	5.3	13
10	Prolonged expression of CD154 on CD4 T cells from pediatric lupus patients correlates with increased CD154 transcription, increased nuclear factor of activated T cell activity, and glomerulonephritis. <i>Arthritis and Rheumatism</i> , 2010 , 62, 2499-509		16
9	Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?. <i>Pediatric Rheumatology</i> , 2010 , 8, 23	3.5	27
8	Rituximab therapy for severe refractory chronic Henoch-Schlelein purpura. <i>Journal of Pediatrics</i> , 2009 , 155, 136-9	3.6	54
7	Optimal treatment of knee monoarthritis in juvenile idiopathic arthritis: a decision analysis. <i>Arthritis and Rheumatism</i> , 2008 , 59, 1580-8		23
6	Evaluation of the presentation of systemic onset juvenile rheumatoid arthritis: data from the Pennsylvania Systemic Onset Juvenile Arthritis Registry (PASOJAR). <i>Journal of Rheumatology</i> , 2008 , 35, 343-8	4.1	93
5	Benefit of fluoroscopically guided intraarticular, long-acting corticosteroid injection for subtalar arthritis in juvenile idiopathic arthritis. <i>Pediatric Radiology</i> , 2007 , 37, 544-8	2.8	34
4	Juvenile idiopathic arthritis classification criteria: loopholes and diagnosis software. <i>Journal of Rheumatology</i> , 2007 , 34, 234; author reply 234-5	4.1	6

- 3 Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. *Journal of Rheumatology*, **2007**, 34, 1133-8 4.1 220
- 2 Variation in the initial treatment of knee monoarthritis in juvenile idiopathic arthritis: a survey of pediatric rheumatologists in the United States and Canada. *Journal of Rheumatology*, **2007**, 34, 1918-24 4.1 17
- 1 Benefit of intraarticular corticosteroid injection under fluoroscopic guidance for subtalar arthritis in juvenile idiopathic arthritis. *Journal of Rheumatology*, **2006**, 33, 2330-6 4.1 23